靛玉红甲肟对奈达铂抗人食管癌EC-1细胞的化疗增效作用

 目的 探讨靛玉红甲肟(Indirubin-3′-monoxime，IRO)与奈达铂联合应用对人食管癌细胞株EC-1的影响及其作用机制。方法 经不同浓度的IRO和(或)奈达铂处理EC-1细胞后，用MTT法测定细胞增殖抑制效应；流式细胞术观察细胞周期变化；免疫组织化学法观察凋亡相关基因表达变化。结果与IRO或奈达铂单药作用相比，IRO与奈达铂联合应用可显著增强人食管癌细胞增殖抑制作用，联合用药后细胞周期分布发生改变，G₀/G₁期细胞比例下降，G₂/M期细胞比例上升，癌细胞Bcl-2基因表达下降，Bax表达增强。结论 IRO与奈达铂联合应用具有协同抗食管癌作用，其机制可能与细胞周期调控及凋亡相关基因表达调控有关。

Anti-tumor Effect of Indirubin-3'-monoxime Combined with Nedaplatin on Human Esophageal Cancer Cell Line EC-1

Objective To study the anti-tumor effect of Indirubin-3'-monoxime combined with Nedaplatin (Nap) on the human esophageal cancer cell line EC-1,and to reveal its methanism. Methods Human esophageal cancer line EC-1 was treated in vitro by Indirubin-3'-monoxime with or without Nap in various concertration. The cell growth was evaluated by MTT assay, cell cycle distribution were observed by flow cytometry, and the expression of apoptosis-related genes were analyzed by immunohistochemical staining method. Results Compared with Indirubin-3'-monoxime or Nap individual drug groups, Indirubin-3'-monoxime combined with Nap obviously increased the inhibitory rate of the human esophageal cancer cell line EC-1. In the groups treated by the combinatio of Indirubin-3'-monoxime and Nap, the cell cycle distribution was altered. In this case, the ratio of G_0/G_1 phase cell decreased, the G_2/M phase cell increased, the expression of Bcl-2 gene down-regulated,and the expression of Bax gene expression up-regulated. Conclusion Indirubin-3'-monoxime combined with Nap may obviously increase the inhibitory rate of the human esophageal cancer cell,and its mechanism may be to regulate cell cycle and to increase apoptosis-inducing effect which is regulated by several genes.